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A B S T R A C T
The aim of this 10-year retrospective study was to investigate the distribution of HCV genotypes in patients with
chronic hepatitis C monitored in the largest center for molecular diagnostics of HCV infection in Croatia. The study en-
rolled 1163 anti-HCV positive adults with detectable HCV RNA in the plasma. The patients were classified in four re-
gions: Zagreb and surrounding continental area, Split, Slavonija and Rijeka. HCV genotyping was performed by using
VERSANT HCV Genotyping Assay (LIPA) (Bayer Diagnostics, Puteaux Cedex, France). Statistical analysis was per-
formed by using Statistica for Windows V. 5.1. The majority of HCV infections in the study population were caused by ge-
notypes 1 (58.8% of infected patients) and 3 (35.6%). Percentages of patients infected with subtypes 1b and 1a were 37.4%
and 13.1%, respectively. Genotypes 2 and 4 were present in a very low percentage of patients (2.2% and 3.4%, respectively)
while genotypes 5 and 6 were not detected. Analysis of regional differences in the distribution of HCV genotypes revealed
similar percentages of subtype 3a and 1b infections in the Split region while the majority of infections in other regions
were caused by subtype 1b. Infections with genotypes 2 and 4 were present in less than 5% of patients in all geographic re-
gions. Analysis of an association between risk factors for infection and distribution of genotypes and subtypes in a subset
of patients from the Split region confirmed the association between IVDU and subtype 3a. We conclude that the preva-
lence of HCV genotypes and subtypes follows the pattern of other Southern and Eastern European Countries with the pre-
dominance of subtypes1b, 3a and 1a.
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Introduction
Infection with hepatitis C virus (HCV) is the major
cause of chronic liver disease leading to liver failure and
hepatocellular carcinoma1. It is estimated that about 170
million persons worldwide are infected with HCV.
HCV is an enveloped Flavivirus with a single-stranded,
positive-sense, non-segmented RNA genome of approxi-
mately 9,400 base pairs that codes for three structural
(core, E1, E2) and seven non-structural (NS2-NS6B and
p7) viral proteins2. A very high degree of genetic heteroge-
neity in regions coding for both structural and non-struc-
tural proteins is one of the key features of this virus.
HCV variants are classified into 6 major genotypes
that are associated with particular risk groups for infec-
tion and often exhibit specific distribution in different
geographical regions. The majority of infections in Eu-
rope, USA and Japan are caused by genotypes 1, 2 and 3
but some genotypes show more restricted geographical
distributions. For example, HCV genotype 2 predomi-
nates in western Africa while the majority of infections
in central Africa are caused by genotypes 1 and 43,4. Ge-
notypes differ from each other in nucleotide sequences
by > 30% and can be further divided into more closely re-
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lated subtypes that differ from each other by 20-25%5.
Some HCV subtypes (1a, 1b and 3a) become widely dis-
tributed due to contaminated blood transfusion and nee-
dle-sharing in intravenous drug users (IDU) and are now
responsible for the majority of infections in the devel-
oped world.
Determination of HCV genotypes is an important di-
agnostic tool for monitoring molecular epidemiology and
determination of the source of HCV transmission, clini-
cal management of chronic infection (response to antivi-
ral therapy) and detection of multiple-genotype infec-
tion1,5,7. Additionally, particular HCV genotypes are also
associated with higher viral load, liver histology and se-
verity of liver disease1,5,7. HCV genotyping is also rele-
vant for the ongoing efforts to develop an efficient HCV
vaccine.
In our earlier study on the molecular epidemiology of
HCV, we showed that the majority of infections in Croa-
tia were caused by subtypes 1b, 3a and 1a6. We also re-
ported a very low prevalence of subtype 2a and genotype
4 infections6. The aim of this 10-year retrospective study
was to investigate the distribution of HCV genotypes and
subtypes in patients with chronic hepatitis C monitored
in the largest center for the molecular diagnostics of
HCV infection in Croatia. We also compared HCV geno-
type distribution in four geographic regions in Croatia
and analysed genotypes according to age, sex and risk
factors for infection.
Materials and Methods
Study design and patients
This retrospective 10 year study was conducted at the
Department for Viral Hepatitis and Outpatient Clinics
for Viral Hepatitis at the University Hospital for Infec-
tious Diseases „Dr. Fran Mihaljevi}«, Zagreb, Croatia be-
tween 1996 and 2005. We enrolled 1163 anti-HCV posi-
tive adults with detectable HCV RNA in the plasma
(determined by the qualitative HCV RNA test COBAS
AMPLICOR HCV version 2.0, Roche Diagnostics, Diag-
nostic System Pleasanton, CA). Median age of female pa-
tients (n=333) was 42 years (range 3–85 years). Median
age of male patients (n=830) was 35 years (range 4-81
years).
The patients were classified in four regions: Zagreb
and surrounding continental area, Split, Slavonija and
Rijeka. Percentages of patients from Zagreb and sur-
rounding continental area, Split, Slavonija and Rijeka in-
cluded in this study were 39.5%, 44.9%, 9.5% and 6.1%,
respectively.
HCV genotyping
Plasma samples for the molecular diagnostics of HCV
infection were collected as a part of the routine diagnos-
tic follow-up of patients with chronic hepatitis C. The
presence of HCV RNA in the samples was determined by
the COBAS AMPLICOR HCV Test, version 2.0 (Roche
Diagnostics, Diagnostic System Pleasanton, CA). HCV
genotyping was performed by using VERSANT HCV
Genotyping Assay (LIPA) (Bayer Diagnostics, Puteaux
Cedex, France) as recommended by the manufacturer.
This line probe assay enables the identification of the fol-
lowing HCV genotypes and subtypes: 1, 1a, 1b, 1a/1b, 2,
2a/2c, 2b, 3, 4, 5a and 6a. HCV genotyping was done by
using otherwise discarded HCV RNA 244-base pairs am-
plicons from COBAS AMPLICOR HCV 2.0 Test (Roche
Diagnostics, Diagnostic System Pleasanton, CA). Molec-
ular HCV assays were performed at the Laboratory for
molecular diagnostics and cellular immunity, University
Hospital for Infectious Diseases »Dr. Fran Mihaljevi}«,
Zagreb, Croatia.
Statistical analysis
Statistical analysis was performed by using Statistica
for Windows V. 5.1 (StatSoft, Inc., Tulsa, USA). Non-
-parametric Kruskal-Walis and Mann-Whitney test were
used.
Results
Distribution of HCV genotypes in Croatia
A ten year retrospective analysis on the distribution
of HCV genotypes in 1163 Croatian patients with chronic
hepatitis C showed that the majority of infections were
caused by genotypes 1 (58.8% of infected patients) and 3
(35.6%) (Table 1). Percentages of patients infected with
subtypes 1b and 1a were 37.4% and 13.1%, respectively.
Genotypes 2 and 4 were present in a very low percentage
of patients (2.2% and 3.4%, respectively) while genotypes
5 and 6 were not detected.
Regional distribution of HCV genotypes
Variability in the distribution of HCV genotypes in
four geographic regions of Croatia is presented in Table 2.
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TABLE 1
DISTRIBUTION OF HEPATITIS C VIRUS (HCV) GENOTYPES AND
SUBTYPES IN 1163 PATIENTS WITH CHRONIC HEPATITIS C IN
CROATIA ANALYSED BETWEEN 1996 AND 2005
HCV geno-
type/subtype
Percentage
of infected
patients
Sex Age in years
median
(range)
Females
(%)
Males
(%)
1 58.8 69.1a 54.7a 42 (3–84)
1a 13.1 13.2 13.0 32 (3–71)
1b 37.4 48.0 33.1 46b (7–84)
2 2.2 3.9 1.6 33 (2–74)
3 35.6 24.0a 40.2a 32 (10–78)
4 3.4 3.0 3.5 31 (22–74)
a difference between females and males is statistically significant
(Mann-Whitney U test, p<0.05 was considered significant)
b significantly different compared with other groups (Kruskal-
-Wallis test and Mann-Whitney U test, p<0.005 for all compari-
sons)
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The majority of HCV infections in three regions in
Croatia (Zagreb and surrounding continental areas, Sla-
vonija and Rijeka) were caused by genotype 1 (69.3%,
60.4% and 76.1%, respectively).
VERSANT HCV Genotyping Assay (LIPA) (Bayer Di-
agnostics, Puteaux Cedex, France) classifies patients in-
fected with HCV genotype 1 as 1a, 1b, 1a/1b and 1. Sub-
type 1b was the predominant in Zagreb and surrounding
continental areas, Slavonija and Rijeka (50.1%, 45.9%
and 46.5% of infected patients, respectively) but not in
the Split region (23.2%). Percentages of subtype 1a infec-
tions were lower compared with subtype 1b infections in
all geographic regions of Croatia. Percentages of patients
infected with HCV genotype 1 that our assay was unable
to determine as 1a or 1b was less than 10% in regions.
Only 3 patients were identified as infected with 1a/1b
HCV subtypes.
The majority of infections in the Split region were
caused by HCV genotype 3 (47.9% of infections) and ge-
notype 1 (46.9%). Percentages of genotype 3 infections in
regions Zagreb and surrounding continental areas, Sla-
vonija and Rijeka region were 25.1%, 32.4% and 18.3%,
respectively. More detailed analysis of genotype 3 infec-
tions (defined as 3a, 3b or 3) revealed that the vast ma-
jority of patients were infected with subtype 3a. Only 1 of
1163 analysed patients was infected with subtype 3b. Ad-
ditionally, 6 patients from the Split and Slavonia groups
were defined as subtype 3 infections and could not be fur-
ther classified with the employed assay.
Percentages of infections with genotypes 2 (mostly
2a/2c) and 4 were less than 5% for all regions.
Age, sex, risk factor for infection and
HCV genotypes
Age and sex distribution in patients infected with dif-
ferent HCV genotypes is presented in Table 1.
Median age of patients infected with subtype 1b was
significantly higher compared with patients infected with
subtype 1a (median 32 years), genotype 3 (median 32
years) and genotype 4 (median 31 years) (p<0.05 for all
comparisons).
Male to female ratio in our patient group was 2.49.
The most frequent HCV genotype in both female and
male patients was genotype 1. Percentages of female
(69.1%) and male (54.7%) patients with genotype 1 infec-
tion were significantly different (p<0.05). Percentage of
genotype 3 infections in male patients (40.2%) was signif-
icantly higher compared with female patients (24.0%).
In order to analyse the possible association between
risk factors for HCV infection and distribution of geno-
types, we analysed a subgroup of 125 patients from the
Split region with complete anamnestic data (Table 3).
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TABLE 2
HEPATITIS C VIRUS (HCV) GENOTYPES AND SUBTYPES IN FOUR GEOGRAPHIC REGIONS IN CROATIA
HCV
genotypes/
subtypes
Number and percentages of patients infected with a particular genotype or subtype within regions
Zagreb and other
continental regions
Split region Slavonija Rijeka region
1 41 (8.9%) 40 (7.7%) 7 (6.3%) 6 (8.5%)
1a 46 (10.0%) 82 (15.7%) 9 (8.1%) 15 (21.1%)
1b 230 (50.1%) 121 (23.2%) 51 (45.9%) 33 (46.5%)
1a/1b 1 (0.2%) 2 (0.4%) 0 0
total number of genotypes 1 318 (69.3%) 245 (46.9) 67 (60.4%) 54 (76.1%)
2 1 (0.2%) 1 (0.2%) 0 0
2a/2c 9 (2.0%) 5 (1.0%) 4 (3.6%) 3 (4.2%)
2b 2 (0.4%) 0 1 (0.9%) 0
total number of genotypes 2 12 (2.6%) 6 (1.2%) 5 (4.5%) 3 (4.2%)
3 0 3 (0.6%) 3 (2.7%) 0
3a 115 (25.1%) 246 (47.1%) 33 (29.7%) 13 (18.3%)
3b 0 1 (0.2%) 0 0
total number of genotypes 3 115 (25.1%) 250 (47.9%) 36 (32.4%) 13 (18.3%)
4 11 (2.4%) 14 (2.7%) 3 (2.7%) 0
4a 1 (0.2%) 0 (0) 0 0
4b 0 1 (0.2%) 0 0
4c/d 2 (0.4%) 5 (1.0%) 0 1 (1.4%)
4h 0 1 (0.2%) 0 0
total number of genotypes 4 14 (3.1%) 21 (4.0%) 3 (2.7%) 1 (1.4%)
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The majority of HCV infections in IVDU group were
caused by subtypes 3a (46 of 76 IVDU patients) and 1a
(18 of 76 IVDU patients).
HCV infection in patients with a history of transfu-
sion/blood product use (n=13 patients) were caused by
subtypes 1a (n=5), 1b (n=4), 3a (n=3) and 2a/2c (n=1).
HCV subtypes in patients with suspected sexual trans-
mission of HCV (n=13 patients) were 3a (n=6), 1b (n=
4), 1a (n=2) and 4 (n=1).
Discussion
This ten-year retrospective analysis on the distribu-
tion of HCV genotypes in 1163 patients with chronic hep-
atitis C in Croatia showed that the majority of infections
were caused by genotypes 1 and 3. Genotypes 5 and 6
were not detected in Croatian HCV patients. Analysis of
regional differences in the distribution of HCV genotypes
revealed the predominance of genotype 3 in the Split re-
gion while the majority of infections in other regions
were caused by subtype 1b. Infections with genotypes 2
and 4 were present in less than 5% of patients in all geo-
graphic regions. Analysis of an association between risk
factors for infection and distribution of genotypes in a
subset of patients from the Split region confirmed the as-
sociation between IVDU and genotype 3.
Distribution of HCV genotypes worldwide is variable
and often associated with specific risk factors for infec-
tion (for review see Simmonds et al, 2004)7. The com-
monest HCV subtype worldwide is subtype 1b whereas
subtype 1a is also widely distributed in northern Europe
and USA and is often associated with IVDU8,9–11. Geno-
type 2 is predominantly found in older patients from
Mediterranean countries and Far East12,13. IVDU is an
important risk factor for infection with genotypes 3 (in
Europe) and 6 (in Asia)8,13–15. Genotype 5 is widely dis-
tributed in Africa. Genotype 4 is often found in Middle
East but can be found in other regions such as Belgium,
Greece and France9,11,16,17.
Countries of Central and Southern/South-Eastern Eu-
rope are characterised by the high prevalence of subtype
1b, particularly in the hyperendemic areas (for example
Central and Southern Italy)13,17–20. Our results showed
that, similarly to neighbouring countries, subtype 1b pre-
dominates in Croatian patients with chronic hepatitis C.
The second most frequent HCV genotype in our study
population was genotype 3 that is often associated with
IVDU. In Western Europe, HCV subtypes 1a and 3a pre-
dominate within IVDU groups but subtypes 4d and 2b
have also entered this population as well8,21. Recent re-
ports described the spread of HCV genotype 4 in some ar-
eas of Europe, particularly south of Belgium16. Unlike in
Western Europe, infections with genotypes 2 and 4 in
Croatia remain uncommon.
Our analysis of HCV genotype regional distribution
showed that the predominant subtype in three out of
four Croatian regions is 1b. However, subtype 3a pre-
dominates in the Split region near the Adriatic coast.
Analysis of genotype/subtype association with risk fac-
tors for infection in the subgroup of patients from the
Split region confirmed the strong association between
subtype 3a infection and IVDU.
The results of our current study are in concordance
with the results of our previous report on the molecular
epidemiology of HCV infection in Croatia that was based
on the analysis of 203 anti-HCV positive patients6. Sub-
type 1b remained the predominant HCV subtype in Cro-
atia, followed by subtypes 3a and 1a. Genotypes 2 and 4
remained a rare finding in Croatian HCV-infected pa-
tients. However, we observed an increase in the percent-
age of patients infected with HCV subtype 3a compared
with the earlier study. Increasing percentages of subtype
3a infections will not only change the molecular epidemi-
ology of HCV infection in Croatia but will have an impor-
tant impact on the overall efficacy of antiviral therapy in
our patients.
In conclusion, the prevalence of HCV genotypes/sub-
types follows the pattern of other Southern and Eastern
European Countries with the predominance of subtypes
1b, 3a and 1a. A retrospective 10 year analysis revealed
increasing percentages of 3a infections and very low
prevalence of genotypes 2 and 4 in Croatian HCV pa-
tients.
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TABLE 3
RISK FACTORS FOR INFECTION AND HEPATITIS C VIRUS (HCV) GENOTYPES AND SUBTYPES
IN 125 PATIENTS FROM THE SPLIT REGION
Risk factor for
infection
Number of patients infected with a particular genotype or subtype within a risk group Total number
of patients1a 1b 2a/2c 3a 4
IVDU 18 10 0 46 2 76
Transfusion 5 4 1 3 0 13
Sexual transmission 2 4 0 6 1 13
Medical procedure 1 5 0 2 1 9
Cosmetic procedure 3 0 0 5 0 8
Professional exposure 2 3 0 1 0 6
IVDU – intravenous drug user
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DISTRIBUCIJA GENOTIPOVA HEPATITIS C VIRUSA U HRVATSKOJ:
DESETOGODI[NJE RETROSPEKTIVNO ISTRA@IVANJE U ^ETIRI REGIJE
S A @ E T A K
Cilj ovog desetogodi{njeg retrospektivnog istra`ivanja bio je analizirati distribuciju genotipova HCV-a u bolesnika s
kroni~nim hepatitisom C koji su pra}eni u najve}em centru za molekularnu dijagnostiku HCV infekcije u R. Hrvatskoj.
U istra`ivanje smo uklju~ili 1163 anti-HCV pozitivne odrasle osobe s mjerljivom HCV RNA u plazmi. Pacijenti su kla-
sificirani u ~etiri regije: Zagreb i okolna kontinentalna podru~ja, Split, Slavonija i Rijeka. Genotipovi HCV-a odre|ivani
su primjenom VERSANT HCV Genotyping Assay (LIPA) (Bayer Diagnostics, Puteaux Cedex, France). Rezultati su
statisti~ki obra|eni primjenom programa Statistica for Windows V. 5.1. Ve}ina pacijenata uklju~enih u istra`ivanje bili
su zara`eni genotipovima 1 (58,8% pacijenata) i 3 (35,6%). 37,4% pacijenata bilo je zara`eno genotipom 1b dok je in-
fekcija genotipom 1a dokazana u 13,1% bolesnika. Broj bolesnika s genotipovima 2 i 4 (2,2% i 3,4%) bili su vrlo mali. U
na{oj skupini bolesnika nismo utvrdili genotipove 5 i 6. Analiza regionalne distribucije HCV genotipova pokazala je
sli~nu zastupljenost subtipova 3a i 1b u Splitu dok je u ve}ine bolesnika iz drugih regija dominirala infekcija subtipom
1b. U svim analiziranim regijama genotipovi 2 i 4 bili su otkriveni u manje od 5% bolesnika. Analiza povezanosti ri-
zi~nih ~imbenika za infekciju HCV-om i distribucije genotipova i subtipova u grupi bolesnika iz Splita potvrdila je
povezanost izme|u IVDU i subtipa 3a. Zaklju~ujemo da je prevalencija genotipova i subtipova HCV-a u R. Hrvatskoj
sli~na onoj u drugim zemljama ju`ne i isto~ne Europe te da dominiraju subtipovi 1b, 3a i 1a.
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